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I heard the statistician say, “The drug 
does not have sufficient activity to study 
further in this population.”  It was my co-
investigator on GOG study 229C, 
Gefitinib in the Treatment of Advanced 
and Recurrent Endometrial Cancer (see 
related extended abstract in this issue*), 
calling from Roswell Park in Buffalo. He 
had just completed the analysis of data 
from 26 women treated on our study – a 
study which had been five years in the 
making from concept to clinical trial. 
These are the most damning words a 
clinical investigator can hear. I thought 
back to the beginning, when our 
preclinical studies indicated a new 
molecular agent, gefitinib, a member of 
a class of small molecules which blocks 
the epidermal growth factor receptor, 
could kill cancer cells in the laboratory. I 
sold the idea to use the drug for patients 
with endometrial cancer to the NIH and 
the pharmaceutical company based 
upon this rosy picture of activity. I 
thought about the seed money we used 
to initiate the trial, which had come from 
the family of a patient who had died of 
the disease, Barbara Beach. The family 
had so hoped that gefitinib would do for 
others what previous treatments failed 
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to do for their mother. They donated 
$250,000.00 in her honor to support this 
trial! 
Then I thought about the patients – 26 
women who had failed all other 
therapies and hoped against hope to 
find a cure in gefitinib. After all, hadn’t 
we shown them the laboratory data?  
Hadn’t we believed ourselves that we 
had found a breakthrough agent? As the 
lead investigator, I was blinded to their 
names and their clinical outcomes until 
the very end of the study….I knew them 
only as numbers, like G17982, etc. I 
knew them only as the blocks of tumor 
tissues sent to my laboratory to study.   
The assays had appeared promising on 
the tissues – why didn’t it work in the 
patients?? 
I said to my colleague, “I can’t believe 
that gefitinib didn’t help anyone – it just 
doesn’t seem possible given our 
preliminary data.”  He replied, “What I 
meant to say is that the drug does not 
have more activity than standard 
chemotherapy.  That doesn’t necessarily 
mean that no one benefited. Let me 
see…..oh yes, I meant to mention that 
patient G55394 had a complete 
response.”   
“You said a complete response? You 
mean she is cured? What does that 
really mean if the drug is not active?”   
“She had a recurrent tumor nodule 
which has now disappeared,” he said in 
a matter of fact statistical tone. “But that 
doesn’t guarantee that it was as a result 
of the drug, you know.”   
I often think of Mrs. G55394 and hope 
she enjoyed the years she lived after 
taking gefitinib – I hope she enjoyed her 
family and all of the important things in 
life. I will never know her personally, but 
she is a big part of my life even now.  
Cancer will never be cured by a single 
drug; I know that now as does 
everybody in the field. Nevertheless, 
some agents work very well for unique 
tumors, and it is now our goal to 
understand why. 
*See “A phase II evaluation of gefitinib in the 
treatment of persistent or recurrent endometrial 
cancer: A Gynecologic Oncology Group study. 
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